Abstract
Short Retraction Notice The paper does not meet the standards of "World Journal of AIDS". This article has been retracted to straighten the academic record. In making this decision the Editorial Board follows COPE's Retraction Guidelines. The aim is to promote the circulation of scientific research by offering an ideal research publication platform with due consideration of internationally accepted standards on publication ethics. The Editorial Board would like to extend its sincere apologies for any inconvenience this retraction may have caused. Editor guiding this retraction: Prof. Linda D. Moneyham (EiC of WJA) Please see the article page for more details. The full retraction notice in PDF is preceding the original paper which is marked "RETRACTED".
Highlights
Chronic hepatitis B virus (HBV) infection is present in 2.7 million of the 36.7C million people infected with the human immunodeficiency virus (HIV) worldwide [1]
Little is known about the prevalence of co-infection with hepatitis B virus (HBV) and human immunodeficiency virus (HIV) in the post-conflict South-Kivu Province, Eastern Democratic Republic of the Congo
The relative high prevalence of HIV/HBV co-infection and chronic nature call for the need of integrating HBV screening programs into HIV routine care to reduce morbidity and mortality levels caused by HIV/HBV co-infection
Summary
Chronic hepatitis B virus (HBV) infection is present in 2.7 million of the 36.7C million people infected with the human immunodeficiency virus (HIV) worldwide [1]. The overall prevalence of HIV/HBV co-infection is estimated at 7.4% with 1.96 million co-infected persons (71%) living in Sub-Saharan Africa [1]. HIV/HBV co-infection is common because of the shared transmission routes for these two viruses, including the parenteral route, the mother-child route and the sexual route. Thas become one of the morbidity and mortality factors including the rapid progression of hepatic lesions to cirrhosis and for hepatocellular carcinoma associated with HBV infection compared to mono-infected HIV or HBV patients. The presence of HBV serological markers was Received: June 12, 2019 Accepted: July 26, 2019 Published: July 29, 2019 determined by enzyme linked immunoassay (ELISA) tests. 33.33% of the subjects had been in contact with HBV and 36.87% were carriers of the immunization marker
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.